These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20133771)

  • 1. Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism.
    Sun X; Barlow EA; Ma S; Hagemeier SR; Duellman SJ; Burgess RR; Tellam J; Khanna R; Kenney SC
    Proc Natl Acad Sci U S A; 2010 Feb; 107(7):3146-51. PubMed ID: 20133771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B Cell-Specific Transcription Activator PAX5 Recruits p300 To Support EBNA1-Driven Transcription.
    Liu CD; Lee HL; Peng CW
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31941781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome.
    Lee EK; Kim SY; Noh KW; Joo EH; Zhao B; Kieff E; Kang MS
    Antiviral Res; 2014 Apr; 104():73-83. PubMed ID: 24486954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
    Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM
    J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells.
    Higashi C; Saji C; Yamada K; Kagawa H; Ohga R; Taira T; Fujimuro M
    Biol Pharm Bull; 2012; 35(5):725-30. PubMed ID: 22687408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
    Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN
    J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GAP31 from an ancient medicinal plant exhibits anti-viral activity through targeting to Epstein-Barr virus nuclear antigen 1.
    Shen CL; Huang WH; Hsu HJ; Yang JH; Peng CW
    Antiviral Res; 2019 Apr; 164():123-130. PubMed ID: 30817940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Basis for Cooperative Binding of EBNA1 to the Epstein-Barr Virus Dyad Symmetry Minimal Origin of Replication.
    Malecka KA; Dheekollu J; Deakyne JS; Wiedmer A; Ramirez UD; Lieberman PM; Messick TE
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31142669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells.
    Hong M; Murai Y; Kutsuna T; Takahashi H; Nomoto K; Cheng CM; Ishizawa S; Zhao QL; Ogawa R; Harmon BV; Tsuneyama K; Takano Y
    J Cancer Res Clin Oncol; 2006 Jan; 132(1):1-8. PubMed ID: 16180023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsp90 inhibitors: a potential treatment for latent EBV infection?
    Sun X; Kenney SC
    Cell Cycle; 2010 May; 9(9):1665-6. PubMed ID: 20404505
    [No Abstract]   [Full Text] [Related]  

  • 11. DNA ligand designed to antagonize EBNA1 represses Epstein-Barr virus-induced immortalization.
    Yasuda A; Noguchi K; Minoshima M; Kashiwazaki G; Kanda T; Katayama K; Mitsuhashi J; Bando T; Sugiyama H; Sugimoto Y
    Cancer Sci; 2011 Dec; 102(12):2221-30. PubMed ID: 21910783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
    Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
    Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth.
    Messick TE; Smith GR; Soldan SS; McDonnell ME; Deakyne JS; Malecka KA; Tolvinski L; van den Heuvel APJ; Gu BW; Cassel JA; Tran DH; Wassermann BR; Zhang Y; Velvadapu V; Zartler ER; Busson P; Reitz AB; Lieberman PM
    Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood.
    Shatzer A; Ali MA; Chavez M; Dowdell K; Lee MJ; Tomita Y; El-Hariry I; Trepel JB; Proia DA; Cohen JI
    Leuk Lymphoma; 2017 Apr; 58(4):923-931. PubMed ID: 27686857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus-encoded EBNA1 enhances RNA polymerase III-dependent EBER expression through induction of EBER-associated cellular transcription factors.
    Owen TJ; O'Neil JD; Dawson CW; Hu C; Chen X; Yao Y; Wood VH; Mitchell LE; White RJ; Young LS; Arrand JR
    Mol Cancer; 2010 Sep; 9():241. PubMed ID: 20843307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Hsp70 inhibitor 2-phenylethynesulfonamide inhibits replication and carcinogenicity of Epstein-Barr virus by inhibiting the molecular chaperone function of Hsp70.
    Wang H; Bu L; Wang C; Zhang Y; Zhou H; Zhang X; Guo W; Long C; Guo D; Sun X
    Cell Death Dis; 2018 Jun; 9(7):734. PubMed ID: 29959331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus nuclear antigen 1 interacts with Nm23-H1 in lymphoblastoid cell lines and inhibits its ability to suppress cell migration.
    Murakami M; Lan K; Subramanian C; Robertson ES
    J Virol; 2005 Feb; 79(3):1559-68. PubMed ID: 15650182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells.
    Sun X; Bristol JA; Iwahori S; Hagemeier SR; Meng Q; Barlow EA; Fingeroth JD; Tarakanova VL; Kalejta RF; Kenney SC
    J Virol; 2013 Sep; 87(18):10126-38. PubMed ID: 23843639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model.
    Hong GK; Gulley ML; Feng WH; Delecluse HJ; Holley-Guthrie E; Kenney SC
    J Virol; 2005 Nov; 79(22):13993-4003. PubMed ID: 16254335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
    Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
    J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.